FierceBiotech January 19, 2026 FDA Grants RMAT Designation to iRegene’s NouvNeu001, Cementing its Lead as the World’s First iPSC Therapy with Both FTD and RMAT Recognitions This article's full content could not be retrieved due to source site restrictions. Read full story on FierceBiotech